On this page
The research desk’s view
The menu describes MOTS-c alongside 5-Amino-1MQ rather than a fully specified standalone offer. No standalone MOTS-c price established from the combined listing.
The listing, in detail
- Published service
- Monroe practice; the page restricts the peptide program to Georgia residents
- Product/menu scope
- The menu describes MOTS-c alongside 5-Amino-1MQ rather than a fully specified standalone offer.
- Cost position
- No standalone MOTS-c price established from the combined listing
- Decision condition
- Confirm exact product, individual eligibility and complete quote before a payment commitment
What the listing establishes
- The menu describes MOTS-c alongside 5-Amino-1MQ rather than a fully specified standalone offer.
- No standalone MOTS-c price established from the combined listing
What it leaves unanswered
- The other named substance changes the proposal. Confirm whether the two are mixed, separately prescribed or simply discussed in one program. A MOTS-c-only evidence appraisal cannot establish the safety or benefit of the combined plan.
- A provider listing does not establish individual eligibility or a clinical benefit.
What a reader can establish
OFH Wellness Center enters this comparison through a specific public listing: the menu describes MOTS-c alongside 5-Amino-1MQ rather than a fully specified standalone offer. The service describes monroe practice; the page restricts the peptide program to Georgia residents. That gives a reader a real place to begin asking questions, while leaving the clinical decision individual. It does not independently verify the pharmacy, establish that the product is appropriate or promise access. The starting evidence guide is useful background because the body's own MOTS-c signal and an administered product answer different research questions.
Why this detail matters
The other named substance changes the proposal. Confirm whether the two are mixed, separately prescribed or simply discussed in one program. A MOTS-c-only evidence appraisal cannot establish the safety or benefit of the combined plan.
The financial question to resolve
The public cost position is: No standalone MOTS-c price established from the combined listing. The written-quote comparison separates a medication amount from the costs of the wider care relationship.
A research finding is not a personal forecast
The distinction becomes clearer in the linked research appraisal. Its setting was INS-1E beta-cell and αTC-1 alpha-cell laboratory lines, and the outcomes concerned insulin, glucagon, peptide secretion and cell viability. Isolated hormone responses cannot establish the net glucose effect or safety in a person. That observation helps a reader ask a narrower question of OFH Wellness Center: which human outcome evidence supports the exact proposal? A scientific reason for interest is not a forecast of a personal response, and a convenient care pathway does not turn the experimental system into a patient treatment trial.
The next comparison to make
For another service model, read the next provider comparison, which concerns telehealth marketing page with an explicit peptide waitlist. The point is to compare the care arrangement and remaining questions, not imply the same product or endorse a clinical outcome. A service with a clearer price can still have unresolved clinical suitability; a consultation with no product guarantee can still provide useful assessment. We have not measured patient experience, support speed or the quality of a supplied preparation at either service.
Read the source
Research findings and provider statements are different evidence.
- OFH Wellness Center official product or clinical-service pageCompany website